Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This study was supported by Instrumentation Laboratory S.p.A. – A Werfen Company, which provided reagents, calibrators, and controls, on behalf of Asahi Kasei Pharma Corporation, its analytical platforms, and support in statistical analysis.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Roohk HV, Zaidi AR. A review of glycated albumin as an intermediate glycation index for controlling diabetes. J Diabetes Sci Technol 2008;2:1114–21.10.1177/193229680800200620Search in Google Scholar PubMed PubMed Central
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86.10.1056/NEJM199309303291401Search in Google Scholar PubMed
3. Ma XJ, Pan JM, Bao YQ, Zhou J, Tang JL, Li Q, et al. Combined assessment of glycated albumin and fasting plasma glucose improves the detection of diabetes in Chinese subjects. Clin Exp Pharmacol Physiol 2010;37:974–9.10.1111/j.1440-1681.2010.05417.xSearch in Google Scholar PubMed
4. Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J 2010;57:751–62.10.1507/endocrj.K10E-138Search in Google Scholar
5. Testa R, Vanhooren V, Bonfigli AR, Boemi M, Olivieri F, Ceriello A, et al. N-Glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. PLoS One 2015;10:e0119983.10.1371/journal.pone.0119983Search in Google Scholar PubMed PubMed Central
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62–9.10.2337/dc10-S062Search in Google Scholar PubMed PubMed Central
7. CLSI. Defining, establishing, and verifying reference intervals in the Clinical Laboratory; approved guideline, 3rd ed. CLSI document EP28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.Search in Google Scholar
8. Kohzuma T, Yamamoto T, Uematsu Y, Shihabi ZK, Freedman BI. Basic performance of an enzymatic method for glycated albumin and reference range determination. J Diabetes Sci Technol 2011;5:1455–62.10.1177/193229681100500619Search in Google Scholar PubMed PubMed Central
9. Araki T, Ishikawa Y, Okazaki H, Tani Y, Toyooka S, Satake M, et al. Introduction of glycated albumin measurement for all blood donors and the prevalence of a high glycated albumin level in Japan. J Diabetes Investig 2012;3:492–7.10.1111/j.2040-1124.2012.00224.xSearch in Google Scholar PubMed PubMed Central
10. Koga M, Murai J, Morita S, Saito H, Kasayama S. Comparison of annual variability in HbA1c and glycated albumin in patients with type 1 vs. type 2 diabetes mellitus. J Diabetes Complications 2013;27:211–3.10.1016/j.jdiacomp.2012.12.001Search in Google Scholar PubMed
©2017 Walter de Gruyter GmbH, Berlin/Boston